Isadora Silveira Ralin

Disease-modifying therapies in Alzheimer's disease: anti-amyloid monoclonal antibodies and clinical perspectives

Background: Alzheimer's disease is characterized by progressive cognitive decline and the accumulation of beta-amyloid and neurofibrillary tangles in the brain. Traditionally, treatments have only been symptomatic, but anti-amyloid monoclonal antibodies, such as lecanemab and donanemab, are emerging as therapies capabl...